Buprenorphine Treatment for Opioid Use Disorder: An Overview

Shulman, Matisyahu; Wai, Jonathan; Nunes, Edward V.

doi:10.1007/s40263-019-00637-z

Cited by 127 publications

(94 citation statements)

References 73 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, research on youth and younger adult populations is a missed opportunity to identify biomarkers that support earlier intervention and better treatment outcomes, which may alleviate the continuation of the disease further into adulthood. Early diagnosis can facilitate harm reduction and prevent the development of infectious diseases such as HIV or hepatitis seen in the adult population with OUD ( 36 , 37 ).…”

Section: Discussionmentioning

confidence: 99%

A Systematic Review of Opioid Use Disorder and Related Biomarkers

Bryant

Eaton

2021

Front. Psychiatry

View full text Add to dashboard Cite

The objective of this systematic review is to examine the relationship between opioid use disorder (OUD) and its related biomarkers, as well as the effects of pharmacotherapy for OUD on biomarkers. The eligibility criteria are the inclusion of human population studies focusing on biomarkers, including the immune system, related to OUD or opioid-related disorders. English, peer reviewed, original research, case studies or case series, and clinical trials were included in this review. Papers were excluded if they met one or more of the following criteria: animal studies, review articles, studies focusing only on OUD or opioid-related disorders without mention of potential biomarkers, studies focusing only on biomarkers and/or the immune system without relating to OUD or opioid-related disorders, and studies that focused on other substance use disorders other than OUD specifically. A PubMed, PsycINFO, and Cochrane databases search on August 25, 2020, yielded 101 results; only 14 articles met inclusion criteria that were included in this review. However, heterogeneity of study definitions and measurements should be noted. Various potential biomarkers indicated systemic, peripheral, and chronic inflammation in patients with OUD or opioid-related disorders. Medications, including buprenorphine and methadone, significantly decreased chronic inflammation in this population. Our results suggest that patients with OUD or opioid-related disorders have potential biomarkers that can be targeted to provide optimal treatment options for this population. A better understanding of potential biomarkers may assist to identify at-risk populations, monitor disease progression and treatment response, and develop therapeutic strategies for OUD.Systematic Review Registration: This review has been registered in PROSPERO (CRD42020202014).

show abstract

Section: Discussionmentioning

confidence: 99%

A Systematic Review of Opioid Use Disorder and Related Biomarkers

Bryant

Eaton

2021

Front. Psychiatry

View full text Add to dashboard Cite

show abstract

“…Naloxone prevents patients from creating a liquid from the sublingual capsules that can then be used as an intravenous (IV) injection. Generally, in the first months of treatment, buprenorphine is only administered by pharmacists, and as a patient gradually gains the health care provider’s trust, they can receive doses to take home [ 15 ]. Overall, however, the abuse potential for buprenorphine is relatively low: the drug is classified by the Food and Drug Administration (FDA) as causing only mild physical dependence.…”

Section: Reviewmentioning

confidence: 99%

Opioid Use Disorder: Treatments and Barriers

Patel

Bunachita

Agarwal

et al. 2021

Cureus

View full text Add to dashboard Cite

Over the last decade, opioid use around the world has risen considerably and is projected to continue to rise at an alarming rate. As opioid use rises, so too does the number of people who suffer from opioid use disorder (OUD) and opioid overdose-related deaths. As science and medicine progresses, new medications and therapies have arisen in order to help treat patients suffering from addiction. Treatment can be split into two main domains: pharmacological and non-pharmacological. Buprenorphine and methadone, currently the most prescribed medications for patients suffering from OUD, have been shown to be extremely effective in clinical trials but have significant real-world limitations. Geographical disparities between various locations, physician stigma with prescribing these medications, and training required to prescribe medication can make access to these treatments difficult for patients. Non-pharmacological interventions have also been shown to help with limited efficacy when combined with pharmacological interventions. However, the time and resources required to implement these strategies may be a difficult barrier to overcome. In this review, we assess pharmacological interventions, non-pharmacological treatments, examine barriers to treatment for patients, and propose solutions to bypass these barriers.

show abstract

“…Buprenorphine is a partial mu opioid receptor agonist with a high binding affinity and a long duration of action. 20 Studies comparing maintenance opioid agonist buprenorphine treatment to tapering and discontinuing the buprenorphine show lower rates of relapse in the buprenorphine maintenance groups. 21 Moderate to severe opioid use disorder can be effectively and safely managed with buprenorphine maintenance in most cases.…”

Section: Medications Assisted Treatment (Mat)mentioning

confidence: 99%

Therapeutic Approaches to Opioid Use Disorder: What is the Current Standard of Care?

Carley¹,

Oesterle²

2021

IJGM

View full text Add to dashboard Cite

Opioid use disorder is a frequent cause of suffering to communities worldwide. Therapeutic approaches to opioid use disorder include screening, appropriate assessment and diagnosis, consideration of level of care, acute management of overdose or withdrawal, treatment with medications, psychotherapeutic approaches, and community support. People who struggle with addiction to opioids often suffer deeply from direct and indirect consequences of use. Subsequently, it is critical that all medical providers understand the appropriate treatment options for opioid use disorder. This paper provides a comprehensive overview of the therapeutic options available for treatment of this chronic disease.

show abstract

Buprenorphine Treatment for Opioid Use Disorder: An Overview

Cited by 127 publications

References 73 publications

A Systematic Review of Opioid Use Disorder and Related Biomarkers

A Systematic Review of Opioid Use Disorder and Related Biomarkers

Opioid Use Disorder: Treatments and Barriers

Therapeutic Approaches to Opioid Use Disorder: What is the Current Standard of Care?

Contact Info

Product

Resources

About